A new year brings exciting new developments in diabetes management.
For the first time, people in the United States who use Abbott’s world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology to manage their diabetes can experience the therapeutic benefits of an automated insulin delivery (AID) system that helps predict and prevent high and low blood sugar.
That’s because Abbott’s new FreeStyle Libre 2 Plus sensor integrates with the t:slim X2 insulin pump from Tandem Diabetes Care Inc.
The FreeStyle Libre 2 Plus sensor, which is the modified FreeStyle Libre 2 sensor cleared in 2023 by the Food & Drug Administration for use with AID systems, is the first and only CGM available in the United States with a wear time of 15 days1 for both adults and children, thereby offering greater convenience and cost savings to people with diabetes.
This is the latest in a series of partnerships aimed at improving and streamlining diabetes care. Last year Abbott integrated its FreeStyle Libre 3 sensor with CamDiab’s CamAPS FX mobile app and Ypsomed’s mylife YpsoPump to implement an AID system in Europe.
The broader reach resulting from these partnerships will strengthen Abbott’s position in the CGM market and expand opportunities for growth.